Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate .
LongeveronFebruary 18, 2021 GMT
MIAMI, Feb. 18, 2021 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the appointments of Douglas Losordo, M.D., Erin Borger, and Cathy Ross to the Company’s Board of Directors.
Douglas Losordo, MD Dr. Losordo has worked in the biotech industry for over twenty years, most recently serving as Executive Vice President, Head of Research and Development and Chief Medical Officer of KBP Biosciences Inc. Dr. Losordo was previously the Executive Vice President, Global Head of Research and Development, Chief Medical Officer of Caladrius Biosciences (Nasdaq: CLBS), a clinical-stage bio
Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate Finance Executives to the Board of Directors
February 18, 2021 08:30 ET | Source: Longeveron Longeveron
MIAMI, Feb. 18, 2021 (GLOBE NEWSWIRE)
Longeveron Inc. (NASDAQ: LGVN) ( Longeveron or Company ), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the appointments of Douglas Losordo, M.D., Erin Borger, and Cathy Ross to the Company’s Board of Directors.
Douglas Losordo, MD
Dr. Losordo has worked in the biotech industry for over twenty years, most recently serving as Executive Vice President, Head of Research and Development and Chief Medical Officer of KBP Biosciences Inc. Dr. Losordo was previously the Executive Vice President, Global Head of Research and Development, Chief Medical Officer of Caladrius Biosciences (Nasdaq: CLBS), a clinical-stage bioph